Susanna Naggie, MD, has been named the new Vice Dean for Clinical Research for the Duke University School of Medicine. Dr. Naggie will begin her service in this role, effective immediately. Dr. Naggie has served as Associate Dean for Clinical Research Initiatives and Regulatory Affairs in the School of Medicine since 2019.
As Vice Dean for Clinical Research, Dr. Naggie will have direct responsibility for advancing the clinical research mission of the School of Medicine, which has one of the largest clinical research portfolios in the country among medical schools. Dr. Naggie will report to the Dean and work closely with School of Medicine, Health System and Campus leaders including the Vice Dean for Translational Sciences, Vice Dean for Data Science and Information Technology, Executive Vice Dean for Administration, and Vice Dean and Executive Director of the Duke Clinical Research Institute (DCRI). She will oversee the Duke Office of Clinical Research (DOCR) and Office of Regulatory Affairs & Quality. Dr. Naggie will work in partnership with Geeta Swamy, MD, Associate Vice President for Research and Vice Dean for Scientific Integrity, who oversees the Office of Scientific Integrity and the Institutional Review Board (IRB). She will also continue her leadership role with the Clinical Research Units (CRUs), working closely with department CRU leadership.
“Dr. Naggie has been a valuable leader to the School of Medicine in her current role as an associate dean. In particular, during the COVID-19 pandemic, she has been a driving force around organizing and coordinating our efforts, providing important, measured guidance,” said Mary E. Klotman, MD, Dean, Duke University School of Medicine. “Dr. Naggie will continue to play a key role in the School’s mission to improve care for patients through the advancement of our clinical research enterprise.”
Dr. Naggie is a physician-scientist focused on the care of patients with HIV and viral hepatitis and leads a research program aimed at understanding the mechanisms of accelerated liver fibrogenesis in this patient population and the development of biomarkers to guide medical decision making. She currently serves as chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and was recently appointed to the NIH COVID-19 Treatment Guidelines Panel. Dr. Naggie earned her MD from Johns Hopkins School of Medicine and completed her internal medicine training at Duke University, where she also served as a chief resident in internal medicine. She completed her Infectious Diseases fellowship training at Duke, joining the faculty in the Division of Infectious Diseases in 2009.